Modulation of humoral immune response to oral BCG vaccination by Mycobacterium bovis BCG Moreau Rio de Janeiro (RDJ) in healthy adults

Journal of Immune Based Therapies and Vaccines

Volumn 4, Issue , 2006, Pages

  Monteiro Maia, Renata ^a   Ortigão de Sampaio, Maria B ^b   Pinho, Rosa T ^c   Castello Branco, Luiz R R ^a,c  

^a Fundacao Ataulpho de Paiva   (Brazil)

^b University of London Cranmer Terrace   (United Kingdom)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G;

ADULT; ANTIBODY PRODUCTION; ARTICLE; BCG VACCINATION; BRAZIL; CELLULAR IMMUNITY; CONTROLLED STUDY; CORRELATION FUNCTION; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; MALE; MYCOBACTERIOSIS; MYCOBACTERIUM BOVIS; NORMAL HUMAN; REVACCINATION; SKIN TEST; TH1 CELL; TH2 CELL; VOLUNTEER;

EID: 33748905165     PISSN: 14768518     EISSN: 14768518     Source Type: Journal    
DOI: 10.1186/1476-8518-4-4     Document Type: Article

References (26)

1. Andersen P: Host response and antigens involved in protective immunity to Mycobacterium tuberculosis. Scand J Immunol 1997, 45:115-131.
2. Andersen P, Doherty TM: The success and failure of BCG - implications for a novel tuberculosis vaccine. Nature Reviews 2005, 3:656-662.
3. Assis A, Carvalho A: Vacinação BCG por via bucal e alergia tuberculínica. O Hospital 1940, XVIII:543-553.
4. Behr MA, Small PM: Has BCG attenuated to impotence? Nature 1997, 389(11):133-134.
5. Behr MA: Comparative genomics of BCG vaccines. Tuberculosis 2001, 81(1/2):165-168.
6. Behr MA: BCG - different strains, different vaccines? Lancet Infectious Diseases 2002, 2:86-92.
7. Benévolo-de Andrade TC, Monteiro-Maia R, Cosgrove C, Castello-Branco LR: BCG Moreau Rio de Janeiro - An oral vaccine against tuberculosis - Review. Mem Inst Oswaldo Cruz 2005, 100(5):459-465.
8. Bosio CM, Gardner D, Elkins KL: Infection of B cell-deficient mice with CDC a clinical isolate of Mycobacterium tuberculosis: delay in dissemination and development of lung pathology. Journal of Immunology 2000, 164:6417-6425.
9. Brown RM, Cruz O, Brennan M, Gennaro ML, Schlesinger L, Sheiky YA, Hoft DF: Lipoarabinomannan-reactive human secretory Immunoglobulin A responses induced by mucosal bacille Calmette-Guérin vaccination. J Infect Dis 2003, 187:513-517.
10. Castello-Branco LRR, Griffin GE, Poulton TA, Dougan G, Lewis DJM: Characterization of the circulating T-cell response after oral immunization of human volunteers with cholera toxin B subunit. Vaccine 1994, 12:65-72.
11. Cohn DL: Use of the Bacillus Calmette-Guérin vaccination for the prevention of tuberculosis: renewed interest in an old vaccine. Am J Med Sci 1997, 313(6):372-376.
12. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, Mosteller F: Efficacy of BCG vaccine in the prevention of tuberculosis - Meta-analysis of the published literature. JAMA 1994, 271(9):698-702.
13. Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME, Burdick E, Fineberg HV: The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 1995, 96(1 Pt 1):29-35.
14. Das SD, Narayanan PR, Kolappan C, Colston MJ: The cytokine response to bacilli Calmette Guérin vaccination in South India. Int J Tuberc Lung Dis 1998, 2(10):836-843.
15. Eddine AN, Kaufmann SHE: Improved protection by recombinant BCG. Microbes and Infection 2005, 7:939-946.
16. Gheorghiu M: BCG-induced mucosal immune responses. Int J Immunopharmacol 1994, 16(5-6):435-44.
17. Griffin GE, Castello-Branco LRR, Ortigão-de-Sampaio MB, Shattock R: Mucosal Immunology and Models of Mucosal HIV Infection. Mem Inst Oswaldo Cruz 1996, 91(3):367-369.
18. Hanson MS, Bansal GP, Langermann S, Stover CK, Orme I: Efficacy and safety of live recombinant BCG vaccines. Dev Biol Stand 1995, 84:229-236.
19. Ho MM, Corbel MJ, Knezevic I, Roumiantzeff M: Report on aWHO consultation on the characterization of BCG strains, WHO, Geneva, Switerland 8-9 December 2004. 1-16.
20. Hoft DF, Brown RM, Belsho RB: Mucosal Bacille Calmette-Guérin vaccination of humans inhibits delayed-type hypersensitivity to purified protein derivative but induces mycobacteria-specific interferon-γ responses. Clin Infect Dis 2000, 30(Suppl 3):S217-22.
21. Huygen K: Plasmid DNA vaccination. Microbes and Infection 2005, 7:932-938.
22. Kaufmann SHE: Protection against tuberculosis: cytokines, T cells and macrophages. Ann Rheum Dis 2002, 61(Suppl II)ii54-ii58.
23. Mostowy S, Tsolaki AG, Small PM, Behr MA: The in vitro evolution of BCG vaccines. Vaccine 2003, 21:4270-4274.
24. Pessolani MCV, Peralta JM, Rumjanek FD, Gomes HM, Melo-Marques MA, Almeida ECC, Saad MHF, Sarno EM: Serology and leprosy: immunoassays comparing immunoglobulin G antibody responses to 28- and 30- kiloDalton proteins purified from Mycobacterium bovis BCG. J Clin Microbiol 1991, 29(10):2285-2290.
25. Raja A: Immunology of tuberculosis. Indian J Med Res 2004, 120:213-232.
26. Williams A, Reljic R, Naylor I, Clark SO, Falero-Diaz G, Singh M, Challacombe S, Marsh PD, Ivanyi J: Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs. Immunology 2004, 111:328-333.